Shanghai Roche Joins 2009 Bowel Cancer Awareness Month Program
This article was originally published in PharmAsia News
Executive Summary
At the recent 2009 'Join Hands with Hope' Bowel Cancer Awareness Month, cancer experts pointed out that early detection is important in raising survival rates and hope for patients. The event is part of the 'Join Hands with Hope' anti-cancer program co-sponsored by Shanghai Roche Pharmaceuticals, the Department of Disease Control under China's Ministry of Health and the Chinese Anti-Cancer Association (PharmAsia News, May 11, 2009). Local experts participate to promote knowledge of bowel cancer prevention and treatment to help patients build confidence. Bowel cancer treatment has made great strides in chemotherapy, prolonging survival time, improving quality of life and reducing relapse rates. (Click here for more - Chinese Language)
You may also be interested in...
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.